# Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

> **NCT06427460** · PHASE2 · RECRUITING · sponsor: **Changhai Hospital** · enrollment: 67 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **RADIATION:** Central-boost ablative dose delivered by stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT06427460
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-12
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427460, "Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06427460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*